Zai Lab Shares Rise 2.6% on Trial

Zai Lab shares rose 2.6% after releasing positive Phase 1 data for its DLL3‑targeting ADC “zoci” in small‑cell lung cancer.
The drug showed a 62.5% confirmed intracranial response at 1.6 mg/kg among 16 patients in a 136‑patient global Phase 1 trial.
In a Phase 1b/2 study, zoci achieved a 38.2% objective response rate in extrapulmonary neuroendocrine carcinoma patients.
Grade 3+ adverse events were neutropenia (9.6%), anemia (8.8%) and thrombocytopenia (3.7%); no neurologic serious events reported.